


Don't suffer the pain of toothache.

Available from Symbion, Sigma, API & CH2

Always read the label and follow the directions for use.



For the temporary relief of pain from toothache.

Today's issue of PD

Pharmacy Daily today features six pages of news including a special feature from SFI Health, plus a full page from WholeLife Pharmacy.

New program

A NEW Opioid Dependence Treatment (ODT) Community Pharmacy Program will commence this year.

The ODT Community Pharmacy Program is planned to start on 01 Jul, with claiming available on the Pharmacy Programs Portal (PPA) during Aug.

The PPA stated the ODT Community Pharmacy Program aims to improve access to and affordability of opioid dependence treatment within the community pharmacy sector, by supporting the delivery of pharmacy services including the staged supply of these medicines and, subject to state and territory legislation and guidelines, pharmacist administration of buprenorphine injections.

The ODT Community Pharmacy Program will allow participating Section 90 pharmacies to submit claims for eligible oral/sublingual and long-acting injectable ODT medications, the PPA shared.

The ODT Community Pharmacy Program Rules are currently being finalised by Health, with more updates available on the PPA site from mid-June onwards.

Vic budget confirms \$19m trial funding

YESTERDAY the Victorian state government handed down its 2023-24 budget, with the figures confirming an allocation of \$18.9 million for "backing pharmacists to boost our health system".

The money will fund a pilot scheme for community pharmacists to treat "straightforward urinary tract infections, common skin conditions, and reissue contraceptive prescriptions," according to the budget papers.

The scope for community pharmacy to administer vaccinations will also expand under the initiative, with the addition of travel vaccinations and more public health vaccinations.

The state government said the funding delivered on its election commitment for a 12-month trial (PD 24 Nov 2022) which will see pharmacists funded to deliver a

range of services, ensuring patients do not face out-of-pocket costs.

Pre-election costing documents indicate a proposed 01 Jul start date for the pilot, with the state government to pay \$20 per consultation to pharmacists, as well as the equivalent of the PBS reimbursement amount so a Victorian will be no worse off getting their treatment at a pharmacy than at a doctor.

PBS contributions are assumed to not be claimable for medications, as pharmacists are not currently a prescribed pathway under Commonwealth legislation.

It's assumed that 50% of people with a condition eligible for treatment will be attending a pharmacist throughout the course of the 12-month trial.

Based on assumptions about the number of pharmacist

consultations and reimbursed scripts, the figures estimate 130,000 UTI treatments with a \$15 average gap per script, plus 231,837 repeat oral contraceptive scripts, 65,933 minor skin conditions costing \$25 on average per script, and 40,921 travel medications, with that figure based on an estimated 818,410 international departures and that one in 10 might need a travel vaccination.

The Victorian budget for 2023/24 also provides funding to increase access to pharmacotherapy and expand Victoria's naloxone supply program as part of a \$333 million commitment to drug treatment and rehabilitation.

Papers note that in 2021/22 there were 15,153 individuals in the pharmacotherapy program, while the 2023/24 allocation targets 14,630 participants.

Blooms awards its top retail managers

FOR the 15th year in a row, Blooms The Chemist hosted its three-day Retail Managers Conference and this year the Royal Randwick's Retail Manager, Shauna McGrath, has been crowned the 2023 Retail Manager of the Year.

McGrath was recognised for her ability to deliver "outstanding results and nurture business growth while demonstrating the important role of community pharmacy in providing excellent customer care and service," said CEO Emmanuel Vavoulas.

The Retail Manager of the Year Runner Up 2023 is Blooms



Rosedale's Carly Barraud.

The Customer Service Winner 2023 is Blooms Yarrowonga, Sandra Mason, while Training Champion of the Year is also Royal Randwick's McGrath.

The Prospan five

SFI Health is sharing clinical research which has demonstrated that the therapeutic ingredient in its Prospan has five mechanisms of action that help relieve a chesty cough.

See more on [page five](#).

Time to diversify

WHOLELIFE Pharmacy and Healthfoods says it's time to diversify, and it will show you how to better your pharmacy's revenues and profit.

See more on the [back page](#).

Your vision is our ambition

With Symbion, you can rely on our experience and solutions, to help you achieve your goals.



Join us today - symbion.com.au



Connecting communities to care

Crucial to invest

THE Society of Hospital Pharmacists Australia (SHPA) has welcomed investment of \$4.9b into Victoria's hospitals, healthcare system and workforce announced in the state's budget.

On behalf of Victorian members and their colleagues, SHPA President Tom Simpson welcomed the \$201m to be invested into the Victorian healthcare workforce but noted the importance of funding across professions.

"It is heartening to see hospital and healthcare positions funded, but whole care teams need to be fully staffed, including crucial hospital pharmacy positions.

"Medicines are our most common intervention & many confer high risk in the hospital setting and on discharge, requiring speciality pharmacist expertise to ensure their safe and timely use."

Dispense calculator out

INTELLIPHARM has launched its Flexible Dispense Calculator and Reporting tool, now available on its StoreIQ software platform, to support community pharmacies in navigating the change to operations associated with the Federal Government's recent 60-day dispensing measure.

The provider of data and technology solutions says its Flexible Dispense Calculator is customisable and incorporates store-specific data.

The company shared that initial feedback from clients who have seen a demonstration of the calculator has been very positive.

Head of Intellipharm Kosta Conomos stated, "we are committed to working with our network of community pharmacies to ensure they have access to insights to help them through the forthcoming changes.

"At Intellipharm, we recognise that each pharmacy's business and customer base is unique.



"By leveraging a pharmacy's unique datasets we have developed a flexible calculator that helps pharmacists to consider the potential impact for themselves.

"We believe pharmacists are best placed to make their assumptions of uptake as they know their customers better than anyone," added Conomos.

"To recognise the loyalty of our customers over a long period, we will be providing these reports free of charge to those customers who currently utilise the StoreIQ platform."

To learn more about Intellipharm's Flexible Dispense Calculator and the latest developments and enhancements to StoreIQ, visit [HERE](#) or call 1300 255 160.

New College CEO


THE Australasian College of Pharmacy has appointed Melanie Hunt as its new Chief Executive Officer commencing 29 May.

College President, Michelle Bou-Samra welcomed Hunt saying, "we are thrilled to have Melanie take the lead as the College embarks on an exciting new era and builds on our existing offerings in professional development and training for the pharmacy industry," and thanked Mark Lock who was interim CEO.

Hunt joins the College with more than 20 years of experience in regulated training industries.

Most recently, Hunt held the position of Chief Operating Officer for General Practice Training Queensland, where she led the transition of staff, systems and processes of the Australian General Practice Training program.

INTRODUCING NEW

 **spikevax™ bivalent**
Original / Omicron BA.4-5
elasomeran / davesomeran
mRNA vaccine

WE'VE UPDATED THE VACCINE AND THE DELIVERY METHOD*1

*Moderna's Spikevax Bivalent Original/Omicron BA.4-5 COVID-19 vaccine. Pre-Filled Syringes replace Spikevax Bivalent Original/Omicron BA.1 multidose vials.1



Boosters provide additional protection against COVID-19

including against symptomatic infection and severe disease when given 6 months after a previous COVID-19 vaccine²⁻⁴

The Pre-Filled Syringe is now available to order for your patients

PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.

▼ This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

BEFORE PRESCRIBING, PLEASE REVIEW PRODUCT INFORMATION AVAILABLE FROM [HTTPS://MODERNACOV19GLOBAL.COM/EN-AU](https://modernacovid19global.com/en-au) OR FROM MODERNA AUSTRALIA ON 1800 344 018.

References: 1. Spikevax Bivalent Original/Omicron BA.4-5 Product Information, February 2023. 2. Chalkias S *et al.* A bivalent Omicron-containing booster vaccine against COVID-19. Available at: <https://www.medrxiv.org/content/10.1101/2022.06.24.22276703v1>. Accessed April 2023. 3. Andersson NW, *et al.* Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries. *medRxiv*. Published online 2023:2023-01. 4. Link-Gelles R *et al.* *MMWR Morb Mortal Wkly Rep* 2022;71:1526-30.

moderna®

Moderna Australia Pty Ltd. Level 6, 60 Martin Place, Sydney, NSW 2000.
© Copyright 2023. Prepared: April 2023. AU-COV-2300023.
MOD0210_PD_EDM_HP



[Click to read](#)

RSV newborn vax

AN ADVISORY committee at the US Food and Drug Administration has voted to recommend an RSV vaccine for pregnant women in their third trimester, to help prevent RSV (respiratory syncytial virus) infections in infants from birth up to six months of age.

Pfizer has submitted the results from a phase 3 trial of a candidate immunisation involving 650 healthy pregnant women, which found an efficacy of 81.8% in the prevention of RSV.

Annaliesa Anderson, Pfizer Chief Scientific Officer of Vaccine R&D, welcomed the recommendation, saying "if approved, our RSV vaccine candidate has the potential to be the first maternal immunisation vaccine to help protect infants at first breath through their first six months of life from this potentially serious infection".

Pharmacy key to UK vision

BRITAIN'S pharmacists would play an enhanced role in a reformed primary care system for the country, under a new major health policy platform unveiled by the UK's opposition Labour party.

A briefing document released earlier this week suggested an increased ability for pharmacists to independently prescribe medications, as well as more empowered pharmacy technicians.

"Whilst the Government has announced some 'sticking plaster' proposals in this area, we will go further, accelerating the roll out of independent prescribing to establish a Community Pharmacist Prescribing Service covering a broad range of common conditions," the party promised.

Red tape will be cut to allow pharmacy technicians to step up to some roles with expanded scope, "ensuring pharmacists can work to the top of their license and focus on their expertise in prescribing and medicines management,

rather than repetitive dispensing processes," according to the document unveiled by Labour leader Keir Starmer.

Labour's enhanced policy also proposes support for greater digital interoperability between pharmacists and GPs, with the aim of helping collaboratively manage long-term conditions such as hypertension and COPD.

Improved technology links with GP practices will also help in "tackling the serious issue of overprescribing, which is responsible for thousands of avoidable hospital admissions every year," the manifesto notes.

Labour's vision for the UK health system will "lead to fewer lives lost to the biggest killers in a fairer Britain, where everyone lives well for longer," the document notes.

Labour is currently leading the conservative government in opinion polls, but the next UK election is currently not scheduled to be held until early 2025.

FIP promotes pharmacy to UN

THIS week's United Nations World Health Assembly in Geneva, Switzerland will see the International Pharmacists' Federation (FIP) strongly advocate for the sector's role.

UN member states will be called on to "leverage pharmacists' expertise and accessibility" with FIP officials highlighting roles in areas such as non-communicable diseases, patient safety and infection control.

The FIP delegation to the assembly includes leaders of several FIP member organisations, some of whom will make official statements on behalf of the Federation, while FIP will also participate in several joint position papers alongside other organisations.

It's the first time the World Health Assembly has been held in-person since the pandemic.

Chemists' Own®

Got cold or flu symptoms?



UP TO 35% DISCOUNT

Deal pricing valid 1 April - 31 July 2023. Available via Turnover only. Contact your Arrotex Territory Manager.

Always read the label and follow the directions for use. Chemists' Own® is a registered trade mark of Arrow Pharmaceuticals Pty Ltd.

KEEP UP TO DATE



Click here to follow Pharmacy Daily on Twitter



Some baby formula claims dismissed

ABBOTT Laboratories has persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula.

In a decision this week, US District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only “economic loss” claims related to Similac and other formula that they said had a “substantial risk” of bacterial contamination.

The parents said they would not have bought or would have paid less for formula but for the Illinois-based company’s claims that it was safe.



But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.

“In short, the plaintiffs received exactly what they say they bargained for: safe infant formula,” Kennelly wrote.

The judge also issued decisions that narrowed but did not dismiss two related lawsuits.

Be ready for the next one

THE head of the World Health Organization urged countries this week to carry out reforms needed to prepare for the next pandemic, hailing their “historic” decision to accept a major budget hike at the UN agency’s annual assembly.

Speaking at the assembly weeks after ending the global emergency status for the COVID-19 pandemic, WHO Director-General, Tedros Adhanom Ghebreyesus (**pictured**), said it was time to advance negotiations on preventing the next pandemic.

“We cannot kick this can down the road,” he said in a major address to the agency’s member states, warning that the next pandemic was bound to “come knocking”.

“If we do not make the changes that must be made, then who will? And if we do not make them now, then when?” he said.

The 10-day annual World Health



Assembly in Geneva, which coincides with the WHO’s 75th anniversary, is set to address global health challenges including future pandemics, eradicating polio and supporting steps to ease Ukraine’s health emergency triggered by Russia’s invasion.

The WHO’s 194 member states are now drafting a pandemic treaty which is up for adoption at next year’s assembly.

“A commitment from this generation is important, because it is this generation that experienced how awful a small virus could be,” said Ghebreyesus.

WE ARE HIRING BUSINESS DEVELOPMENT EXECUTIVE

- Drive sales across Pharmacy Daily
- Full time, flexible hours
- Generous remuneration package commensurate with experience
- Based at Macquarie Park, NSW

The Business Publishing Group, a leading independent publisher in business-to-business news titles is looking for a proactive candidate to join our close knit team.

You will be responsible for contributing to the sales of our leading pharmacy news title Pharmacy Daily, as well as assist across other publications in the group and projects helping to achieve revenue targets.

If you have at least three years’ advertising sales experience, know how to close a deal and can work autonomously as well as within a team, this could be your next rewarding role.

Pharmacy Daily

To apply email your confidential CV with cover letter to jobs@traveldaily.com.au before 26/05/23.

Mandatory testing for cough syrups

INDIA will allow the export of cough syrups only after samples are tested in a government laboratory, a government notice declared yesterday, after Indian-made cough syrups were linked to the deaths of some children in Gambia and Uzbekistan.

Any cough syrup must have a certificate of analysis issued by a govt laboratory before it is exported, effective 01 Jun, the government said in a notice.

“Cough syrup shall be permitted to be exported

subject to the export sample being tested and production of certificate of analysis,” the notice issued by the country’s trade ministry stated.

Indian-made cough syrups were linked to the deaths of 70 children in Gambia and 19 in Uzbekistan last year, denting the image of India’s US \$41 billion (A\$61.67 billion) pharmaceutical industry.

India was also considering a change to its pharmaceutical industry policy.

Time to rethink your dispensary set-up?

CONSIS.C The latest in pharmacy robotic automation

No matter the size of your pharmacy, contact us for a confidential discussion to explore the options available.

www.willach.com.au
Tel: (03) 9429 8222
info@willach.com.au

find out more

Willach | Pharmacy Solutions



Content produced in collaboration with SFI Health.

Clinical Evidence For EA 575: Chesty Cough Relief



A **UNIQUE** Ivy leaf extract, known as EA 575[®] has been found to contain a specific combination of active constituents that are responsible for a distinguishing characteristic: five mechanisms of action that help to relieve cough and congestion.

An extensive body of over 20 clinical studies, involving over 65,000 patients, has demonstrated not only therapeutic benefits for both adults and children but also that this quality is specific to EA 575^{2,3,4}.

Clinical trials have shown that EA 575 significantly improves cough symptoms and leads to faster resolution compared to a placebo.

EA 575 was shown to relieve a cough twice as fast than when left untreated*, with patients reporting feeling well or very well following treatment.

The effectiveness of EA 575 is attributed to its five mechanisms of action.

EA 575[®] has a long history of use and high levels of tolerability, with retrospective studies showing an incredibly low 0.22% incidence of side effects in children⁵.

Exclusively used as the active ingredient in Prospan, learn more about how EA 575 compares **HERE**.

*Always read the label and follow the directions for use. *Prospan is clinically proven to relieve a chesty cough in 7 days vs 14 days untreated. Schaefer A, et al., Pharmazie 2016;71(9):504-509.*

What's in a cough?

THE cough reflex is a natural defence mechanism that acts to protect the respiratory tract, reminds SFI Health.

Viral infections, such as the common cold or the flu, are by far the most common causes of cough¹.

Activated when receptors in the upper airways are activated by triggers or irritants, the cough reflex is linked to two types of nerve pathways involving different receptors: the mechano-sensitive receptors found primarily in the larynx and chemo-sensitive receptors found in the distal airways.

Coughs are one of the most frequent reasons people seek medical advice, and duration is an important part of diagnostic assessment.

Five action cough relief



SFI Health has shared research which has demonstrated that EA 575[®], the unique therapeutic ingredient in Prospan, has five separate mechanisms of action that help relieve a chesty cough. These mechanisms are:

- Thinning and loosening mucus
- Clearing stubborn chest congestion
- Soothing & relaxing the airways
- Calming the chest
- Relieving inflammation

REFERENCES: 1. Cough. Healthdirect. Viewed 1 April 2021.; 2. Volp A, Schmitz J, Bulitta M, Raskopf E, Cengizhan A, Mosges R. Ivy leaves extract EA575 in the treatment of cough during acute respiratory tract infections: meta-analysis of double-blind, randomised, placebo-controlled trials. *Sci Rep* 2022; 12: 20041.; 3. Lang C, Rottger-Luer P, Staiger C. A valuable option for the treatment of respiratory diseases: review of the clinical evidence of the ivy leaves dry extract EA575[®]. *Planta Med* 2015; 81 (12/13): 968-974.; 4. Schulte-Michels J, Runkel F, Gokorsch S, Haberlein H. Ivy leaves dry extract EA575[®] decreases LPS-induced IL-6 release from murine macrophages. *Pharmazie* 2016; 71 (3): 158-61.; 5. Kraft K. *Zeitschrift für Phytotherapie* 2004;25:179-181.






HELPS TAKE THEIR COUGH AWAY

Offer your customers a clinically proven* 5 action formula for chesty coughs

Always read the label and follow the directions for use. *Reference: 1. Lang C, et al., *Planta Med* 2015;81:968-974. Supported by Engelhard Arzneimittel GmbH & Co. KG.

Dispensary Corner

AN AUSTRALIAN strongman has added a fourth Guinness World Records (GWR) title to his name by using his bare hands to spin a Ferris wheel around in 16 mins and 55 secs, easily beating the time limit set to 30 mins.

Troy Conley-Magnusson, 39, achieved the feat at Sydney's Luna Park recently to raise funds for the charity Little Wings, which benefits seriously ill children and their families.

Conley-Magnusson dedicated his attempt to the memory of an 11-year-old named Zac, who died last year.

"He was the strongest 11-year-old I'd ever met and my absolute hero," the strongman told GWR.

"This record is dedicated to his memory and strength which far outweighs mine."

GWR required the Ferris wheel to have at least 24 cars, each weighing at least 1,543 pounds. The total structure had to have a total weight of at least 99,208 pounds.

The amusement park ride was set into "freewheeling" mode, meaning the hydraulics and brakes were completely disengaged.

"This is by far one of the hardest physical and mental challenges I have ever undertaken, and I'd done some pretty extreme feats of strength over the years," Conley-Magnusson said.

The bodybuilder's previous records include the heaviest vehicle pushed over 100 ft, the fastest 20-metre light aircraft pulled with the teeth, and also most cars pulled with the teeth.

Intimate data apps need monitoring

MENSTRUATION monitoring apps are among the latest innovations in 'FemTech', but Flinders University law experts Prof Tania Leiman and Lydia Chia explain that the legal implications of who can access this highly personal data from ovulation apps and how can it be used are not clearly understood.

"As we use apps to monitor more and more about how our bodies function, we need to think carefully about where that data is going and what the unintended consequences - both legal and otherwise - of generating that data might be," said Leiman.

"People who menstruate should understand the bargain they are making; is convenience worth giving up your most intimate privacy and data security?"

Period trackers or ovulation



apps monitor menstrual cycles to provide insights into fertility windows and period symptoms, identifying patterns unique to an individual user's cycle.

Predictions of ovulation days or when the next period will occur are based on data collected from the user, ranging from mood changes and frequency of cramps, to sexual habits and basal body temperature.

The growing popularity of these tools has even seen leading health apps, such as Fitbit and Garmin,

incorporate period tracking as an additional feature to its other fitness tracking services, while Apple's CycleTracker is a standard feature in the Health App on iPhones.

However, while app users consent to privacy policies that contain varying levels of data and privacy protection, standards regulating data processing, sharing and storage of personal information differ depending on the location in which an ovulation app's company is domiciled.

In Australia, data gathered by ovulation apps fall within the protections for 'personal', 'sensitive' and 'health information' in the Privacy Act, although it's not clear whether it could be also regarded as 'biometric information' or a 'biometric template'.

PRODUCT SPOTLIGHT

Suppliers wanting to promote products in this feature should email newproducts@pharmacydaily.com.au

Melrose Marine Collagen Complex + Astaxanthin Liposomal

Melrose Collagen Complex + Astaxanthin Liposomal brings together the latest in nutrient delivery technology to support radiant skin from within. Our cutting-edge formula contains the power of Marine Collagen, vitamin C, Astaxanthin and Vitamin E to help achieve healthy skin.

Enhanced bioavailability and rapid absorption.

Easy-to-take, liquid formula makes it simple to incorporate essential vitamins into your daily routine.

Supplier: Speak to your Pharmabroker Sales Representative for a launch special.

RRP: \$37.95

Website: [CLICK HERE](#) for more information.





WHOLELIFE

PHARMACY & HEALTHFOODS



IS 2023 THE YEAR THAT YOU ARE GOING TO MAKE A CHANGE FOR THE BETTER?

Are you:

1. Looking for ways to increase revenue and profit for your pharmacy?
2. Worried that your pharmacy isn't standing out in the ever-crowded pharmacy sector?
3. Concerned that you don't seem to be tapping into the latest trends in the health and wellness market?
4. Keen to introduce new categories, new services and new products for the changing market, but don't know where to start?
5. Looking for the next big thing in pharmacy?

IT IS TIME TO *diversify!*

WholeLife Pharmacy and Healthfoods is Australia's leading health and wellbeing pharmacy destination. We have a proven pharmacy model that has been shown to support increased revenue and profit for established pharmacies driving new foot traffic, larger basket sizes and increased customer frequency.

WholeLife is transforming the future of retail pharmacy and providing our store owners with the opportunity to diversify, expand and future proof their businesses, as the market for wholistic and healthy living continues to grow.

DOES THIS SOUND LIKE YOU? KEEN TO LEARN MORE?

Register your interest at www.wholelife.com.au/join-us to arrange a confidential discussion.



MIKE MCKENNA - HEAD OF NETWORK DEVELOPMENT
E: mike.mckenna@wholelife.com.au | M: +61 497 407 001

Thank You, Mike McKenna

The evolution of pharmacy is here!